Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal

Stock Track

Aug 10

REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement with AbbVie.

The biotech firm previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan — a dramatic turnaround from a net loss of 4.5 billion yuan in the prior-year period. The stellar performance was primarily driven by sustained domestic sales growth of its core products Telitacicept and Disitamab Vedotin, alongside a significant boost in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which includes an upfront payment of 650 million USD and a total deal value of up to 5.6 billion USD.

Additional positive catalysts include the recently published new National Essential Drug List, which is expected to create further volume expansion opportunities for the company's key products. The broader biotech sector also showed strength, with peers such as 3SBIO, AKESO, and INNOVENT BIO posting gains, creating a favorable spillover effect for REMEGEN.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152719908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152719908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152719908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152719908","market":"us","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal","media":"Stock Track","content":"<p>REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement with AbbVie.</p><p>The biotech firm previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan — a dramatic turnaround from a net loss of 4.5 billion yuan in the prior-year period. The stellar performance was primarily driven by sustained domestic sales growth of its core products Telitacicept and Disitamab Vedotin, alongside a significant boost in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which includes an upfront payment of 650 million USD and a total deal value of up to 5.6 billion USD.</p><p>Additional positive catalysts include the recently published new National Essential Drug List, which is expected to create further volume expansion opportunities for the company's key products. The broader biotech sector also showed strength, with peers such as 3SBIO, AKESO, and INNOVENT BIO posting gains, creating a favorable spillover effect for REMEGEN.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-10 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement with AbbVie.</p><p>The biotech firm previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan — a dramatic turnaround from a net loss of 4.5 billion yuan in the prior-year period. The stellar performance was primarily driven by sustained domestic sales growth of its core products Telitacicept and Disitamab Vedotin, alongside a significant boost in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which includes an upfront payment of 650 million USD and a total deal value of up to 5.6 billion USD.</p><p>Additional positive catalysts include the recently published new National Essential Drug List, which is expected to create further volume expansion opportunities for the company's key products. The broader biotech sector also showed strength, with peers such as 3SBIO, AKESO, and INNOVENT BIO posting gains, creating a favorable spillover effect for REMEGEN.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1152719908","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152719908","pubTimestamp":1786326518,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"股票跟踪 | REMEGEN 因上半年利润好转和艾伯维授权协议盘中飙升 5.10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) surged 5.10% during the intraday session on Monday, extending its rally as investors reacted positively to the company's mid-year earnings preview and a lucrative licensing agreement with AbbVie.The biotech firm previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan — a dramatic turnaround from a net loss of 4.5 billion yuan in the prior-year period. The stellar performance was primarily driven by sustained domestic sales growth of its core products Telitacicept and Disitamab Vedotin, alongside a significant boost in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which includes an upfront payment of 650 million USD and a total deal value of up to 5.6 billion USD.Additional positive catalysts include the recently published new National Essential Drug List, which is expected to create further volume expansion opportunities for the company's key products. The broader biotech sector also showed strength, with peers such as 3SBIO, AKESO, and INNOVENT BIO posting gains, creating a favorable spillover effect for REMEGEN.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}